|
1
|
Kilfoy BA, Zheng T, Holford TR, Han X,
Ward MH, Sjodin A, Zhang Y, Bai Y, Zhu C, Guo GL, et al:
International patterns and trends in thyroid cancer incidence,
1973–2002. Cancer Causes Control. 20:525–531. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
American Thyroid Association (ATA)
Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid
Cancer, ; Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL,
Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, et
al: Revised American Thyroid Association management guidelines for
patients with thyroid nodules and differentiated thyroid cancer.
Thyroid. 19:1167–1214. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pitoia F, Ward L, Wohllk N, Friguglietti
C, Tomimori E, Gauna A, Camargo R, Vaisman M, Harach R, Munizaga F,
et al: Recommendations of the Latin American Thyroid Society on
diagnosis and management of differentiated thyroid cancer. Arq Bras
Endocrinol Metabol. 53:884–887. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pacini F, Schlumberger M, Dralle H, Elisei
R, Smit JW and Wiersinga W; European Thyroid Cancer Taskforce, :
European consensus for the management of patients with
differentiated thyroid carcinoma of the follicular epithelium. Eur
J Endocrino. 154:787–803. 2006. View Article : Google Scholar
|
|
5
|
Iida F, Yonekura M and Miyakawa M: Study
of intragladular dissemination of thyroid cancer. Cancer.
24:764–771. 1969. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tscholl-Ducommun J and Hedinger CE:
Papillary thyroid carcinomas. Morphology and prognosis. Virchows
Arch A Pathol Anat Histol. 396:19–39. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Katoh R, Sasaki J, Kurihara H, Suzuki K,
Iida Y and Kawaoi A: Multiple thyroid involvement (intraglandular
metastasis) in papillary thyroid carcinoma. A clinicopathologic
study of 105 consecutive patients. Cancer. 70:1585–1590. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pitt SC, Sippel RS and Chen H:
Contralateral papillary thyroid cancer: Does size matter? Am J Sur.
197:342–347. 2009. View Article : Google Scholar
|
|
9
|
Hawk WA and Hazard JB: The many
appearances of papillary carcinoma of the thyroid. Cleve Clin Q.
43:207–215. 1976. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mazzaferri EL and Jhiang SM: Long-term
impact of initial surgical and medical therapy on papillary and
follicular thyroid cancer. Am J Med. 97:418–428. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hay ID, Thompson GB, Grant CS, Bergstralh
EJ, Dvorak CE, Gorman CA, Maurer MS, McIver B, Mullan BP, Oberg AL,
et al: Papillary thyroid carcinoma managed at the Mayo Clinic
during six decades (1940–1999): Temporal trends in initial therapy
and long-term outcome in 2444 consecutively treated patients. World
J Surg. 26:879–885. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gemsenjager E, Perren A, Seifert B,
Schuler G, Schweizer I and Heitz PU: Lymph node surgery in
papillary thyroid carcinoma. J Am Coll Surg. 197:182–190. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lyon MF: X-chromosome inactivation: A
repeat hypothesis. Cytogenet Cell Genet. 80:133–137. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lyon MF: X-chromosome inactivation and
developmental patterns in mammals. Biol Rev Camb Philos Soc.
47:1–35. 1972. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Allen RC, Zoghbi HY, Moseley AB,
Rosenblatt HM and Belmont JW: Methylation of HpaII and HhaI
sites near the polymorphic CAG repeat in the human
androgen-receptor gene correlates with X chromosome inactivation.
Am J Hum Genet. 51:1229–1239. 1992.PubMed/NCBI
|
|
16
|
McCarthy RP, Wang M, Jones TD, Strate RW
and Cheng L: Molecular evidence for the same clonal origin of
multifocal papillary thyroid carcinomas. Clin Cancer Res.
12:2414–2418. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cheng L, Gu J, Eble JN, Bostwick DG,
Younger C, MacLennan GT, Abdul-Karim FW, Geary WA, Koch MO, Zhang S
and Ulbright TM: Molecular genetic evidence for different clonal
origin of components of human renal angiomyolipomas. Am J Surg
Pathol. 25:1231–1236. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cheng L, Gu J, Ulbright TM, MacLennan GT,
Sweeney CJ, Zhang S, Sanchez K, Koch MO and Eble JN: Precise
microdissection of human bladder carcinomas reveals divergent tumor
subclones in the same tumor. Cancer. 94:104–110. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Davies L and Welch HG: Current thyroid
cancer trends in the United States. JAMA Otolaryngol Head Neck
Surg. 140:317–322. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pacini F and De Groot LJ: Thyroid cancer.
endotext.org, version of July 1, 2016, published by. simpleMDText.comInc.(South Dartmouth, MA).
02748https://www.ncbi.nlm.nih.gov/books/NBK285543/
|
|
21
|
Bongarzone I, Butti MG, Coronelli S,
Borrello MG, Santoro M, Mondellini P, Pilotti S, Fusco A, Della
Porta G and Pierotti MA: Frequent activation of ret protooncogene
by fusion with a new activating gene in papillary thyroid
carcinomas. Cancer Res. 54:2979–2985. 1994.PubMed/NCBI
|
|
22
|
Cohen Y, Xing M, Mambo E, Guo Z, Wu G,
Trink B, Beller U, Westra WH, Ladenson PW and Sidransky D: BRAF
mutation in papillary thyroid carcinoma. J Natl Cancer Inst.
95:625–627. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fagin JA: Challenging dogma in thyroid
cancer molecular genetics-role of RET/PTC and BRAF in tumor
initiation. J Clin Endocrinol Metab. 89:4264–4266. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sozzi G, Bongarzone I, Miozzo M, Borrello
MG, Blutti MG, Pilotti S, Della Porta G and Pierotti MA: A t(10;17)
translocation creates the RET/PTC2 chimeric transforming sequence
in papillary thyroid carcinoma. Genes Chromosomes Cancer.
9:244–250. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kimura ET, Nikiforova MN, Zhu Z, Knauf JA,
Nikiforov YE and Fagin JA: High prevalence of BRAF mutations in
thyroid cancer: genetic evidence for constitutive activation of the
RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.
Cancer Res. 63:1454–1457. 2003.PubMed/NCBI
|
|
26
|
Cancer Genome Atlas Research Network, .
Integrated genomic characterization of papillary thyroid carcinoma.
Cell. 159:676–690. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xing M: Molecular pathogenesis and
mechanisms of thyroid cancer. Nat Rev Cancer. 13:184–199. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Park SY, Park YJ, Lee YJ, Lee HS, Choi SH,
Choe G, Jang HC, Park SH, Park DJ and Cho BY: Analysis of
differential BRAF(V600E) mutational status in multifocal papillary
thyroid carcinoma: evidence of independent clonal origin in
distinct tumor foci. Cancer. 107:1831–1838. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhu Z, Ciampi R, Nikiforova MN, Gandhi M
and Nikiforov YE: Prevalence of RET/PTC rearrangements in thyroid
papillary carcinomas: effects of the detection methods and genetic
heterogeneity. J Clin Endocrinol Metab. 91:3603–3610. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Aherne ST, Smyth PC, Flavin RJ, Russell
SM, Denning KM, Li JH, Guenther SM, O'Leary JJ and Sheils OM:
Geographical mapping of a multifocal thyroid tumour using genetic
alteration analysis and miRNA profiling. Mol Cancer. 7:892008.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Moniz S, Catarino AL, Marques AR, Cavaco
B, Sobrinho L and Leite V: Clonal origin of non-medullary thyroid
tumours assessed by non-random X-chromosome inactivation. Eur J
Endocrinol. 146:27–33. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shattuck TM, Westra WH, Ladenson PW and
Arnold A: Independent clonal origins of distinct tumor foci in
multifocal papillary thyroid carcinoma. N Engl J Med.
352:2406–2412. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Nakazawa T, Kondo T, Tahara I, Kasai K,
Inoue T, Oishi N, Mochizuki K, Kubota T and Katoh R: Multicentric
occurrence of multiple papillary thyroid carcinomas-HUMARA and BRAF
mutation analysis. Cancer Med. 4:1272–1280. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang W, Wang H, Teng X, Wang H, Mao C,
Teng R, Zhao W, Cao J, Fahey TJ III and Teng L: Clonal analysis of
bilateral, recurrent, and metastatic papillary thyroid carcinomas.
Hum Pathol. 41:1299–1309. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kuhn E, Teller L, Piana S, Rosai J and
Merino MJ: Different clonal origin of bilateral papillary thyroid
carcinoma, with a review of the literature. Endocr Pathol.
23:101–107. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Siu IM, Robinson DR, Schwartz S, Kung HJ,
Pretlow TG, Petersen RB and Pretlow TP: The identification of
monoclonality in human aberrant crypt foci. Cancer Res. 59:63–66.
1999.PubMed/NCBI
|
|
37
|
El Kassar N, Hetet G, Brière J and
Grandchamp B: X-chromosome inactivation in healthy females:
incidence of excessive lyonization with age and comparison of
assays involving DNA methylation and transcript polymorphisms. Clin
Chem. 44:61–67. 1998.PubMed/NCBI
|
|
38
|
Jovanovic L, Delahunt B, McIver B,
Eberhardt NL and Grebe SK: Thyroid gland clonality revisited: The
embryonal patch size of the normal human thyroid gland is very
large, suggesting X-chromosome inactivation tumor clonality studies
of thyroid tumors have to be interpreted with caution. J Clin
Endocrinol Metab. 88:3284–3291. 2003. View Article : Google Scholar : PubMed/NCBI
|
